Department of Cardiology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
J Cardiovasc Electrophysiol. 2020 May;31(5):1202-1210. doi: 10.1111/jce.14445. Epub 2020 Mar 28.
His-Purkinje system pacing has been demonstrated as a synchronized ventricular pacing strategy via pacing His-Purkinje system directly, which can decrease the incidence of adverse cardiac structure alteration compared with right ventricular pacing (RVP). The purpose of this meta-analysis was to compare the effects of His-Purkinje system pacing and RVP in patients with bradycardia and cardiac conduction dysfunction.
PubMed, Embase, Cochrane Library, and Web of Science were systematically searched from the establishment of databases up to 15 December 2019. Studies on long-term clinical outcomes of His-Purkinje system pacing and RVP were included. Chronic paced QRS duration, chronic pacing threshold, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), all-cause mortality, and heart failure hospitalization were collected for meta-analysis.
A total of 13 studies comprising 2348 patients were included in this meta-analysis. Compared with RVP group, patients receiving His-Purkinje system pacing showed improvement of LVEF (mean difference [MD], 5.65; 95% confidence interval [CI], 4.38-6.92), shorter chronic paced QRS duration (MD, - 39.29; 95% CI, - 41.90 to - 36.68), higher pacing threshold (MD, 0.8; 95% CI, 0.71-0.89) and lower risk of heart failure hospitalization (odds ratio [OR], 0.65; 95% CI, 0.44-0.96) during the follow-up. However, no statistical difference existed in LVEDV, LVESV and all-cause mortality between the two groups.
Our meta-analysis suggests that His-bundle pacing is more suitable for the treatment of patients with bradycardia and cardiac conduction dysfunction.
通过直接起搏希氏-浦肯野系统,希氏-浦肯野系统起搏已被证明是一种同步心室起搏策略,与右心室起搏(RVP)相比,它可以降低不良心脏结构改变的发生率。本荟萃分析的目的是比较希氏-浦肯野系统起搏和 RVP 在心动过缓和心脏传导功能障碍患者中的疗效。
系统检索了 PubMed、Embase、Cochrane Library 和 Web of Science 从数据库建立到 2019 年 12 月 15 日的文献,纳入了希氏-浦肯野系统起搏和 RVP 长期临床结局的研究。收集慢性起搏 QRS 时限、慢性起搏阈值、左心室射血分数(LVEF)、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、全因死亡率和心力衰竭住院率进行荟萃分析。
本荟萃分析共纳入 13 项研究,共 2348 例患者。与 RVP 组相比,接受希氏-浦肯野系统起搏的患者 LVEF 改善(平均差异 [MD],5.65;95%置信区间 [CI],4.38-6.92)、慢性起搏 QRS 时限缩短(MD,-39.29;95% CI,-41.90 至-36.68)、起搏阈值升高(MD,0.8;95% CI,0.71-0.89)和心力衰竭住院风险降低(比值比 [OR],0.65;95% CI,0.44-0.96)。然而,两组在 LVEDV、LVESV 和全因死亡率方面无统计学差异。
本荟萃分析表明,希氏束起搏更适合治疗心动过缓和心脏传导功能障碍患者。